Revenue Breakdown
Composition ()
No data
Revenue Streams
Glaukos Corp (GKOS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Glaucoma, accounting for 83.4% of total sales, equivalent to $103.53M. Another important revenue stream is Corneal Health. Understanding this composition is critical for investors evaluating how GKOS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Glaukos Corp maintains a gross margin of 77.80%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -18.87%, while the net margin is -93.39%. These profitability ratios, combined with a Return on Equity (ROE) of -26.38%, provide a clear picture of how effectively GKOS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, GKOS competes directly with industry leaders such as BLCO and BIO. With a market capitalization of $6.99B, it holds a significant position in the sector. When comparing efficiency, GKOS's gross margin of 77.80% stands against BLCO's 58.08% and BIO's 49.74%. Such benchmarking helps identify whether Glaukos Corp is trading at a premium or discount relative to its financial performance.
